NasdaqGS:HOLX

Stock Analysis Report

Executive Summary

Hologic, Inc., a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally.

Snowflake

Fundamentals

Adequate balance sheet with reasonable growth potential.


Similar Companies

Share Price & News

How has Hologic's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-1.0%

HOLX

1.7%

US Medical Equipment

2.3%

US Market


1 Year Return

17.7%

HOLX

10.1%

US Medical Equipment

5.6%

US Market

Return vs Industry: HOLX exceeded the US Medical Equipment industry which returned 10.1% over the past year.

Return vs Market: HOLX exceeded the US Market which returned 5.6% over the past year.


Shareholder returns

HOLXIndustryMarket
7 Day-1.0%1.7%2.3%
30 Day-1.0%-1.7%-1.0%
90 Day1.0%-1.7%-0.7%
1 Year17.7%17.7%11.0%10.1%7.9%5.6%
3 Year27.6%27.6%70.4%65.2%45.6%36.3%
5 Year101.4%101.4%128.5%103.2%65.8%47.6%

Price Volatility Vs. Market

How volatile is Hologic's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Hologic undervalued compared to its fair value and its price relative to the market?

18.0%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: HOLX ($48.97) is trading below our estimate of fair value ($59.76)

Significantly Undervalued: HOLX is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: HOLX is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: HOLX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate HOLX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: HOLX is overvalued based on its PB Ratio (5.9x) compared to the US Medical Equipment industry average (3.7x).


Next Steps

Future Growth

How is Hologic forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?

49.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HOLX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).

Earnings vs Market: HOLX is forecast to become profitable over the next 3 year, which is considered above average market growth.

High Growth Earnings: HOLX's loss is forecast to worsen by 0% next year.

Revenue vs Market: HOLX's revenue (3.6% per year) is forecast to grow slower than the US market (7.3% per year).

High Growth Revenue: HOLX's revenue (3.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: HOLX's Return on Equity is forecast to be high in 3 years time (25.7%)


Next Steps

Past Performance

How has Hologic performed over the past 5 years?

14.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: HOLX is unprofitable, but has reduced losses over the past 5 years at a rate of 14.5% per year.

Accelerating Growth: Unable to compare HOLX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HOLX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: HOLX has a negative Return on Equity (-1.34%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: HOLX is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: HOLX is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Hologic's financial position?


Financial Position Analysis

Short Term Liabilities: HOLX's short term assets ($1.6B) exceeds its short term liabilities ($1.0B)

Long Term Liabilities: HOLX's short term assets (1.6B) do not cover its long term liabilities (3.3B)


Debt to Equity History and Analysis

Debt Level: HOLX's debt to equity ratio (137.8%) is considered high

Reducing Debt: HOLX's debt to equity ratio has reduced from 208.5% to 137.8% over the past 5 years.


Balance Sheet

Inventory Level: HOLX has a low level of unsold assets or inventory.

Debt Coverage by Assets: HOLX's debt is not covered by short term assets (assets are 0.5x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable HOLX has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: HOLX is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 6.1% per year.


Next Steps

Dividend

What is Hologic's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.2%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate HOLX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate HOLX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if HOLX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HOLX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HOLX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Hologic's salary, the management and board of directors tenure and is there insider trading?

4.7yrs

Average management tenure


CEO

Steve MacMillan (55yo)

5.8yrs

Tenure

US$42,040,142

Compensation

Mr. Stephen P. MacMillan, also known as Steve, has been the Chairman of the Board at Hologic Inc. since June 17, 2015 and its Chief Executive Officer and President since December 9, 2013. Mr. MacMillan ser ...


CEO Compensation Analysis

Compensation vs. Market: Steve's total compensation ($USD42.04M) is about average for companies of similar size in the US market ($USD11.23M).

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

4.7yrs

Average Tenure

55.5yo

Average Age

Experienced Management: HOLX's management team is considered experienced (4.7 years average tenure).


Board Age and Tenure

2.8yrs

Average Tenure

58yo

Average Age

Experienced Board: HOLX's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$200,98606 Mar 19
Peter Valenti
EntityIndividual
Role
Unit President
Division President of Breast & Skeletal Health Solutions
Shares4,242
Max PriceUS$47.38
SellUS$200,02811 Dec 18
Peter Valenti
EntityIndividual
Role
Unit President
Division President of Breast & Skeletal Health Solutions
Shares4,740
Max PriceUS$42.20
SellUS$273,00020 Nov 18
Allison Bebo
EntityIndividual
Role
Head of Human Resources
Senior Vice President of Human Resources
Shares6,500
Max PriceUS$42.00

Ownership Breakdown


Management Team

  • Jay Stein (76yo)

    Co-Founder

    • Tenure: 12yrs
    • Compensation: US$1.59m
  • Steve MacMillan (55yo)

    Chairman

    • Tenure: 5.8yrs
    • Compensation: US$42.04m
  • Karleen Oberton (49yo)

    Chief Financial Officer

    • Tenure: 1.2yrs
    • Compensation: US$3.02m
  • Michael Watts

    Vice President of Investor Relations & Corporate Communications

    • Tenure: 0yrs
  • Pete Valenti (56yo)

    Division President of Breast & Skeletal Health Solutions

    • Tenure: 5.4yrs
    • Compensation: US$2.04m
  • John Griffin (58yo)

    General Counsel

    • Tenure: 4.7yrs
    • Compensation: US$2.43m
  • Ali Bebo (50yo)

    Senior Vice President of Human Resources

    • Tenure: 4.7yrs
  • Jan Verstreken

    Regional President for Europe

    • Tenure: 0yrs
  • Sanjay Prabhakaran

    Regional President of Asia Pacific

    • Tenure: 0yrs
  • Monica Berthelot

    Chief of Staff

    • Tenure: 0.8yrs

Board Members

  • Jay Stein (76yo)

    Co-Founder

    • Tenure: 12yrs
    • Compensation: US$1.59m
  • Steve MacMillan (55yo)

    Chairman

    • Tenure: 5.8yrs
    • Compensation: US$42.04m
  • Scott Garrett (69yo)

    Independent Director

    • Tenure: 6.4yrs
    • Compensation: US$278.49k
  • Sally Crawford (65yo)

    Lead Independent Director

    • Tenure: 2.8yrs
    • Compensation: US$357.68k
  • Ludwig Hantson (56yo)

    Independent Director

    • Tenure: 0.9yrs
  • Charles Dockendorff (65yo)

    Independent Director

    • Tenure: 2.4yrs
    • Compensation: US$273.99k
  • Christiana Stamoulis (48yo)

    Independent Director

    • Tenure: 7.9yrs
    • Compensation: US$266.49k
  • Namal Nawana (48yo)

    Independent Director

    • Tenure: 1.8yrs
    • Compensation: US$264.94k
  • Amy Wendell (58yo)

    Independent Director

    • Tenure: 2.8yrs
    • Compensation: US$266.49k

Company Information

Hologic, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Hologic, Inc.
  • Ticker: HOLX
  • Exchange: NasdaqGS
  • Founded: 1985
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$13.090b
  • Shares outstanding: 267.31m
  • Website: https://www.hologic.com

Number of Employees


Location

  • Hologic, Inc.
  • 250 Campus Drive
  • Marlborough
  • Massachusetts
  • 1752
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HOLXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMar 1990
HO1DB (Deutsche Boerse AG)YesCommon StockDEEURMar 1990
HOLXWBAG (Wiener Boerse AG)YesCommon StockATEURMar 1990
0J5QLSE (London Stock Exchange)YesCommon StockGBUSDMar 1990
HOLX *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNMar 1990

Biography

Hologic, Inc., a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacif ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/16 23:35
End of Day Share Price2019/10/16 00:00
Earnings2019/06/29
Annual Earnings2018/09/29


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.